Janus Henderson HF Biotechnology A2 USD (LU1897414303)
44.84
+1.13
(+2.59%)
USD |
Aug 25 2026
Returns Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Key Stats
| Net Expense Ratio | Total Assets Under Management | Weighted Average Dividend Yield | Turnover Ratio (Generic) |
|---|---|---|---|
| -- | -- | -- | -- |
| 1 Year Fund Level Flows | 1 Year Total Returns (Daily) | Annualized Total Returns Since Inception (Daily) | Max Drawdown (Since Inception) |
| -- | -- |
Basic Info
| Investment Strategy | |
| None |
| General | |
| Security Type | None |
| Equity Style | None |
| Broad Asset Class | None |
| Broad Category | None |
| Global Peer Group | None |
| Peer Group | None |
| Global Macro | None |
| US Macro | None |
| YCharts Categorization | -- |
| YCharts Benchmark | -- |
| Prospectus Objective | None |
| Fund Owner Firm Name | None |
| Broad Asset Class Benchmark Index | |
| None | |
Net Fund Flows Versus Peer Group
1 Month
% Rank:
--
--
Peer Group Low
--
Peer Group High
1 Year
% Rank:
--
--
Peer Group Low
--
Peer Group High
3 Months
% Rank:
--
--
Peer Group Low
--
Peer Group High
3 Years
% Rank:
--
--
Peer Group Low
--
Peer Group High
6 Months
% Rank:
--
--
Peer Group Low
--
Peer Group High
5 Years
% Rank:
--
--
Peer Group Low
--
Peer Group High
YTD
% Rank:
--
--
Peer Group Low
--
Peer Group High
10 Years
% Rank:
--
--
Peer Group Low
--
Peer Group High
Date Unavailable
Risk
Performance Versus Peer Group
Annual Total Returns Versus Peers
As of August 26, 2026.
Asset Allocation
| Type | % Net |
|---|
Top 10 Holdings
| Name | % Weight | Price | % Change |
|---|---|---|---|
| Revolution Medicines, Inc. | 5.95% | 212.82 | 0.68% |
| Praxis Precision Medicines, Inc. | 4.74% | 378.50 | 2.85% |
| BridgeBio Pharma, Inc. | 4.01% | 79.59 | -1.01% |
| argenx SE | 3.90% | 1046.09 | 2.61% |
| Gilead Sciences, Inc. | 3.87% | 148.70 | -0.05% |
| Travere Therapeutics, Inc. | 3.56% | 67.10 | 0.13% |
| PTC Therapeutics, Inc. | 3.23% | 73.04 | -0.59% |
| Vertex Pharmaceuticals, Inc. | 3.21% | 549.11 | -0.68% |
| Ascendis Pharma A/S | 3.03% | 250.60 | -0.94% |
| Mirum Pharmaceuticals, Inc. | 2.81% | 98.33 | 0.25% |
Fees & Availability
| Fees | |
| Actual 12B-1 Fee | -- |
| Actual Management Fee | -- |
| Administration Fee | -- |
| Maximum Front Load | -- |
| Maximum Deferred Load | -- |
| Maximum Redemption Fee | -- |
| General Availability | |
| Available for Insurance Product | -- |
| Available for RRSP | -- |
| Purchase Details | |
| Open to New Investors | -- |
| Minimum Initial Investment | -- |
| Minimum Subsequent Investment | -- |
Projected Income
| Type | Aug | Sep | Oct | Nov | Dec | Jan | Feb | Mar | Apr | May | Jun | Jul |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Qualified Income
|
-- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
|
Normal
|
-- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
|
Qualified
|
-- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
|
LT Cap Gains
|
-- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
|
Ordinary Income
|
-- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
|
Non-Qual
|
-- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
|
ST Cap Gains
|
-- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
|
Interest
|
-- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
|
Tax-Exempt
|
-- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
|
ROC
|
-- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
|
Other
|
-- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
|
Total
|
-- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
As of July 31, 2026.
Basic Info
| Investment Strategy | |
| None |
| General | |
| Security Type | None |
| Equity Style | None |
| Broad Asset Class | None |
| Broad Category | None |
| Global Peer Group | None |
| Peer Group | None |
| Global Macro | None |
| US Macro | None |
| YCharts Categorization | -- |
| YCharts Benchmark | -- |
| Prospectus Objective | None |
| Fund Owner Firm Name | None |
| Broad Asset Class Benchmark Index | |
| None | |
Fundamentals
| General | |
| Distribution Yield | -- |
| Dividend Yield TTM | -- |
| 30-Day SEC Yield | -- |
| 7-Day SEC Yield | -- |
| Number of Holdings | -- |
| Stock | |
| Weighted Average PE Ratio | -- |
| Weighted Average Price to Sales Ratio | -- |
| Weighted Average Price to Book Ratio | -- |
| Weighted Median ROE | -- |
| Weighted Median ROA | -- |
| Return on Investment (TTM) | -- |
| Earning Yield | -- |
| LT Debt / Shareholders Equity | -- |
| Number of Equity Holdings | -- |
Growth Metrics
| EPS Growth (1Y) | -- |
| EPS Growth (3Y) | -- |
| EPS Growth (5Y) | -- |
| Sales Growth (1Y) | -- |
| Sales Growth (3Y) | -- |
| Sales Growth (5Y) | -- |
| Sales per Share Growth (1Y) | -- |
| Sales per Share Growth (3Y) | -- |
| Operating Cash Flow - Growth Rate (3Y) | -- |
Fund Details
| Key Dates | |
| Inception Date | -- |
| Last Annual Report Date | -- |
| Last Prospectus Date | -- |
| Share Classes | |
| LU1897414485 | -- |
| LU1897414568 | -- |
| LU1897414642 | -- |
| LU1897415292 | -- |
| LU1984712759 | -- |
| LU1988887292 | -- |
| LU2304361343 | -- |
| LU2342243362 | -- |
| LU2351303867 | -- |
| LU2441282626 | -- |
| LU2441282899 | -- |
| LU2441282972 | -- |
| LU2441283277 | -- |
| LU2832952142 | -- |
| LU2900274890 | -- |
| LU2900274973 | -- |
| LU2900275194 | -- |
| LU2900275277 | -- |
| LU2900275350 | -- |
| LU2900275434 | -- |
| LU3202695717 | -- |
| LU3311969912 | -- |
| Attributes | |
| Index Fund | -- |
| Inverse Fund | -- |
| Leveraged Fund | -- |
| Fund of Funds | -- |
| Currency Hedged Fund | -- |
| Socially Responsible Fund | -- |
Top Portfolio Holders
| Name | % Weight |
|---|---|
| Portfolio A | 5.00% |
| Portfolio B | 3.50% |
| Portfolio C | 2.25% |
Excel Add-In Codes
| Name: =YCI("M:LU1897414303", "name") |
| Broad Asset Class: =YCI("M:LU1897414303", "broad_asset_class") |
| Broad Category: =YCI("M:LU1897414303", "broad_category_group") |
| Prospectus Objective: =YCI("M:LU1897414303", "prospectus_objective") |
| To find the codes for any of our securities and financial metrics, see our Complete Excel Reference. |